Who are S. boulardii's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): "AS-Probionorm", Akkermansia muciniphila + Infliximab, Saccharomyces boulardi (Sb), Combizym + Bifidobacteri, "Probiotics" and "Metronidazole", Probiotic Vivomixx.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/s-boulardii.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

S. boulardii — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

S. boulardii (S. boulardii) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Gastrointestinal.

phase 3 Probiotic Gastrointestinal Small molecule Live · refreshed every 30 min

Target snapshot

S. boulardii (S. boulardii) — Muhammad Aamir Latif. S. boulardii is a probiotic yeast that helps maintain a healthy gut microbiome.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
S. boulardii TARGET	S. boulardii	Muhammad Aamir Latif	phase 3	Probiotic
"AS-Probionorm"	"AS-Probionorm"	Industrial Microbiology LLP	marketed	Probiotic
Akkermansia muciniphila + Infliximab	Akkermansia muciniphila + Infliximab	Chinese Medical Association	marketed	Combination therapy: probiotic + TNF-α inhibitor	TNF-α (infliximab component); gut microbiota modulation (Akkermansia muciniphila component)
Saccharomyces boulardi (Sb)	Saccharomyces boulardi (Sb)	Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan	marketed	Probiotic
Combizym + Bifidobacteri	Combizym + Bifidobacteri	RenJi Hospital	marketed	Enzyme and probiotic combination
"Probiotics" and "Metronidazole"	"Probiotics" and "Metronidazole"	Peking University Shenzhen Hospital	marketed	Antibiotic + Probiotic combination
Probiotic Vivomixx	Probiotic Vivomixx	University of Milan	marketed	Probiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). S. boulardii — Competitive Intelligence Brief. https://druglandscape.com/ci/s-boulardii. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab